abrdn Life Sciences Investors Shares of Beneficial Interest (HQL)
Cost of Revenue
$10.91M
TTM · Period ending: · USD
HQL Cost of Revenue
Latest reported$10.91Mperiod ending
Latest reported$10.91Mperiod ending
HQL TTM Cost of Revenue ($3.23M → $10.91M)
TTM cost of revenue
High-resolution chart · PNG
HQL cost of revenue history
Trailing twelve months (TTM) · USD. Each value covers four complete reported quarters.
| Period ending | Cost of Revenue (USD) |
|---|---|
| 10,913,133 | |
| 10,327,942 | |
| 10,474,439 | |
| 10,601,299 | |
| 10,418,785 | |
| 10,792,997 | |
| 11,307,520 | |
| 11,624,986 | |
| 11,703,136 | |
| 11,282,054 | |
| 8,177,161 | |
| 5,206,018 | |
| 2,484,709 | |
| 0 | |
| 4,820,280 | |
| 4,820,280 | |
| 4,820,280 | |
| 4,820,280 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 2,480,000 | |
| 3,990,000 | |
| 5,500,000 | |
| 6,995,000 | |
| 6,010,000 | |
| 5,925,000 | |
| 5,840,000 | |
| 6,225,000 | |
| 6,610,000 | |
| 6,995,000 | |
| 7,380,000 | |
| 6,965,000 | |
| 6,550,000 | |
| 6,145,000 | |
| 5,740,000 | |
| 5,665,000 | |
| 5,590,000 | |
| 5,405,000 | |
| 5,220,000 | |
| 5,260,000 | |
| 5,300,000 | |
| 5,710,000 | |
| 6,120,000 | |
| 5,510,000 | |
| 4,900,000 | |
| 4,085,000 | |
| 3,270,000 | |
| 3,250,000 | |
| 3,230,000 |